Ketamine vs ECT: Head-to-Head Trial Results

For decades, electroconvulsive therapy (ECT) has been considered the gold standard for treatment-resistant depression (TRD). It works, but it comes with significant drawbacks: general anesthesia, cognitive side effects, and the logistical burden of repeated hospital visits. Ketamine has emerged as a potential alternative, and a 2024 secondary analysis published in JAMA Network Open put the two treatments head-to-head.

This post examines the specific trial data. For a broader comparison of ketamine and ECT as treatment modalities, see our comprehensive comparison page.

The Trial Design

The analysis drew from a randomized controlled trial that directly compared intravenous ketamine infusions to ECT in patients with TRD. This was not a meta-analysis or observational study; patients were randomly assigned to one treatment or the other, making the comparison as rigorous as clinical research allows.

The secondary analysis published in JAMA Network Open in 2024 examined several outcomes beyond the primary endpoint, including response and remission rates, speed of improvement, cognitive effects, and quality of life measures. This deeper look at the data provides a more nuanced picture than the top-line results alone.

What the Data Showed

Antidepressant Efficacy

The trial found that ketamine and ECT produced comparable antidepressant effects. Both treatments led to significant reductions in depression scores, and the response and remission rates were statistically similar between the two groups. This finding alone is remarkable: ketamine, a treatment that can be administered in an outpatient or even at-home setting, matched a procedure that requires general anesthesia and a full medical team.

Cognitive Outcomes

This is where the data diverged significantly. ECT was associated with measurable cognitive side effects, particularly in memory and executive function, that persisted beyond the treatment period. Ketamine, by contrast, showed minimal cognitive impact. For many patients, especially those in the workforce or managing daily responsibilities, this difference is clinically meaningful.

Speed of Response

Both treatments acted relatively quickly compared to traditional antidepressants, which typically require four to six weeks to take effect. However, ketamine showed a trend toward faster initial improvement, with some patients reporting mood changes within hours of their first infusion. ECT responses typically became apparent after several sessions over one to two weeks.

Tolerability and Side Effects

Ketamine's side effects during infusions, primarily dissociation, dizziness, and mild nausea, were transient and resolved within hours. ECT's side effects, including post-procedure confusion, headaches, and the cognitive effects noted above, tended to be more disruptive to daily life.

Why This Comparison Matters

The clinical significance of these findings extends beyond the numbers. ECT has long been positioned as the treatment of last resort, the option when everything else has failed. The fact that ketamine can match its efficacy while offering a better cognitive and tolerability profile challenges that hierarchy.

For patients facing the ECT decision, the data suggests ketamine deserves serious consideration as an alternative, not a compromise. This is especially true given the practical advantages: ketamine infusions do not require general anesthesia, can be administered in outpatient settings, and sublingual formulations now allow physician-supervised at-home treatment.

Limitations to Consider

No single trial settles a clinical question definitively. Several caveats apply:

• Sample size: While adequate for detecting meaningful differences, larger trials would strengthen confidence in the results.
• Patient selection: The trial enrolled patients meeting specific TRD criteria. Results may not generalize to all depression subtypes.
• Long-term outcomes: The secondary analysis examined outcomes over a defined follow-up period. Longer-term comparisons of maintenance ECT versus maintenance ketamine are still needed.
• Blinding challenges: Ketamine's dissociative effects make true blinding difficult, a recurring methodological issue in ketamine research.

What This Means for Patients

If you have been told that ECT is your next step, this trial data suggests you have options worth discussing with your treatment team. Ketamine's comparable efficacy, paired with its more favorable cognitive and tolerability profile, makes it a legitimate alternative for many patients with TRD.

Isha Health's clinical outcomes data demonstrates strong real-world response rates with physician-led at-home ketamine therapy, consistent with the efficacy observed in controlled trial settings.

The decision between ketamine and ECT should be individualized, taking into account your specific depression history, treatment response, cognitive concerns, and practical considerations. But the 2024 trial data makes clear that ketamine belongs in the conversation alongside ECT, not beneath it.

Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.